Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessio Bruni

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2023
Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)Giulio Francolini, Andrea Gaetano Allegra, Beatrice Detti, et al.
Medical Oncology (Northwood, London, England)|May 19, 2021
Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistanceLuca Triggiani, Rosario Mazzola, Davide Tomasini, et al.
La Radiologia Medica|October 13, 2019
Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetingsDavide Franceschini, Alessio Bruni, Paolo Borghetti, et al.
Cancers|June 2, 2021
How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO)Ercole Mazzeo, Luca Triggiani, Luca Frassinelli, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 16, 2025
Dose-intensified SBRT for vertebral oligometastases: results from a prospective clinical trialMatthias Guckenberger, Lotte Wilke, Charlotte Billiet, et al.
Plos One|November 2, 2019
Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR)Michela Buglione, Marianna Noale, Alessio Bruni, et al.
European Urology|October 4, 2021
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES StudyCristina Masini, Cinzia Iotti, Ugo De Giorgi, et al.
The Lancet. Oncology|June 29, 2026
SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trialGiulio Francolini, Vanessa Di Cataldo, Saverio Caini, et al.
La Radiologia Medica|March 5, 2022
Stereotactic or conventional radiotherapy for macroscopic prostate bed recurrence: a propensity score analysisGiulio Francolini, Barbara Alicja Jereczek-Fossa, Vanessa Di Cataldo, et al.
Plos One|November 14, 2019
Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approachAlessio Bruni, Niccolò Giaj-Levra, Patrizia Ciammella, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2023
Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)Giulio Francolini, Andrea Gaetano Allegra, Beatrice Detti, et al.
Medical Oncology (Northwood, London, England)|May 19, 2021
Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistanceLuca Triggiani, Rosario Mazzola, Davide Tomasini, et al.
La Radiologia Medica|October 13, 2019
Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetingsDavide Franceschini, Alessio Bruni, Paolo Borghetti, et al.
Cancers|June 2, 2021
How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO)Ercole Mazzeo, Luca Triggiani, Luca Frassinelli, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 16, 2025
Dose-intensified SBRT for vertebral oligometastases: results from a prospective clinical trialMatthias Guckenberger, Lotte Wilke, Charlotte Billiet, et al.
Plos One|November 2, 2019
Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR)Michela Buglione, Marianna Noale, Alessio Bruni, et al.
European Urology|October 4, 2021
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES StudyCristina Masini, Cinzia Iotti, Ugo De Giorgi, et al.
The Lancet. Oncology|June 29, 2026
SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trialGiulio Francolini, Vanessa Di Cataldo, Saverio Caini, et al.
La Radiologia Medica|March 5, 2022
Stereotactic or conventional radiotherapy for macroscopic prostate bed recurrence: a propensity score analysisGiulio Francolini, Barbara Alicja Jereczek-Fossa, Vanessa Di Cataldo, et al.
Plos One|November 14, 2019
Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approachAlessio Bruni, Niccolò Giaj-Levra, Patrizia Ciammella, et al.
Pageof 8